-
A New Frontier in Cancer Research: Understanding Merck’s Remigromig
NYSE: $MRK Targeting the Wnt Pathway In a significant move for oncology research, Merck has initiated a Phase 1 clinical trial to evaluate its investigational agent, remigromig. This novel therapy represents a sophisticated approach to cancer treatment, specifically designed as a tri-specific agonist of the Wingless-related integration site (Wnt) pathway. What is Remigromig? Remigromig is…
-
Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
NYSE: $MRK Tokyo – (September 25, 2026) – The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada… Source: Read More
-
A Breakthrough in Oncology: Merck and Moderna Report Positive Phase 3 Results for Personalized Cancer Vaccine
NYSE: $MRK A Major Milestone in Cancer Treatment The landscape of cancer therapy is evolving rapidly, and a recent announcement from Merck and Moderna marks a significant turning point. The companies have officially announced that the Phase 3 INTERPATH-001 trial, investigating their investigational individualized neoantigen therapy (INT), known as mRNA-4157 (telixavastat/intismeran), combined with the immunotherapy…